3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
147
Melanoma
122
Breast Neoplasms
98
Squamous Cell Carcinoma of Head and Neck
96
Triple Negative Breast Neoplasms
85
Lung Neoplasms
64
Neoplasm Metastasis
53
Carcinoma, Renal Cell
49
Neoplasms
46
Head and Neck Neoplasms
46
Colorectal Neoplasms
41
Ovarian Neoplasms
38
Carcinoma, Transitional Cell
37
Carcinoma, Hepatocellular
36
Pancreatic Neoplasms
35
Urinary Bladder Neoplasms
34
Recurrence
33
Stomach Neoplasms
32
Glioblastoma
30
Brain Neoplasms
28
Sarcoma
26
Endometrial Neoplasms
25
Prostatic Neoplasms
23
Hodgkin Disease
22
Uterine Cervical Neoplasms
19
Fallopian Tube Neoplasms
19
Carcinoma, Squamous Cell
19
Esophageal Squamous Cell Carcinoma
17
Adenocarcinoma
17
Multiple Myeloma
16
Interventions
Bendamustine Hydrochloride
3
fludarabine
2
Cyclophosphamide
2
Brentuximab Vedotin
2
pembrolizumab
1
ibritumomab tiuxetan
1
fludarabine phosphate
1
Standard of Care
1
Rituximab
1
Radiotherapy
1
Melphalan
1
Etoposide
1
Cytarabine
1
Carmustine
1
Bone Marrow Transplantation
1
AP 1903 reagent
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphatic Diseases
×
pembrolizumab
×
Clear all
NCT03349450
2026-05-06
SPiReL
Sunnybrook Health Sciences Centre
Phase 2
Completed
25 enrolled
18 charts